[HTML][HTML] Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
EG Leprieur, C Dumenil, C Julie, V Giraud… - European journal of …, 2017 - Elsevier
Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
[引用][C] Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
EG Leprieur, C Dumenil, C Julie, V Giraud… - European Journal of …, 2017 - cir.nii.ac.jp
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and
new challenges | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
new challenges | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
C Dumenil, C Julie, V Giraud, J Dumoulin… - European Journal of …, 2017 - europepmc.org
Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
EG Leprieur, C Dumenil, C Julie, V Giraud… - European Journal of …, 2017 - infona.pl
Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
EG Leprieur, C Dumenil, C Julie… - … journal of cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
EG Leprieur, C Dumenil, C Julie, V Giraud… - European Journal of …, 2017 - ejcancer.com
Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …